Valuation: Norda ASA

Market Cap 513M 55.09M 47.21M 44.23M 40.4M 76.25M 5.25B 77M 522M 203M 2.65B 207M 202M 8.77B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.38M 24.32M 22.79M 20.81M 39.28M 2.71B 39.67M 269M 105M 1.36B 107M 104M 4.52B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
6 months+1.53%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+6.67%+110.73% 47.68M
+1.02%+4.95%+3.67%+25.46% 51.21B
-0.05%-2.23%+492.07%+537.27% 45.35B
-0.61%+7.93%+37.78%+18.29% 42.84B
+2.00%+2.67%+22.80%+91.02% 42.29B
-2.27%-5.67%+14.55%+50.34% 32.15B
-1.50%+3.64%+31.06%+135.47% 17.31B
+0.34%+1.19% - - 16.55B
+1.12%+6.35%+11.00%+32.62% 14.84B
-0.05%+6.87%+81.81%+48.89% 14.25B
Average +0.16%+2.90%+77.93%+116.68% 27.68B
Weighted average by Cap. +0.14%+2.89%+105.35%+136.20%

Financials

2023 2024
Net sales 86.92M 9.33M 8M 7.49M 6.84M 12.92M 890M 13.04M 88.37M 34.4M 449M 35.04M 34.27M 1.49B 372M 39.92M 34.21M 32.05M 29.28M 55.25M 3.81B 55.8M 378M 147M 1.92B 150M 147M 6.36B
Net income 31.17M 3.35M 2.87M 2.69M 2.45M 4.63M 319M 4.68M 31.69M 12.34M 161M 12.56M 12.29M 533M 126M 13.52M 11.59M 10.86M 9.92M 18.71M 1.29B 18.9M 128M 49.85M 650M 50.77M 49.66M 2.15B
Net Debt -311M -33.41M -28.63M -26.83M -24.51M -46.25M -3.19B -46.7M -316M -123M -1.61B -125M -123M -5.32B -249M -26.71M -22.89M -21.45M -19.59M -36.97M -2.55B -37.34M -253M -98.48M -1.28B -100M -98.11M -4.25B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock